Entyvio safely treats immunotherapy-induced enterocolitis

PHILADELPHIA – Treatment with Entyvio for immunotherapy-induced enterocolitis demonstrated favorable outcomes and a good safety profile, according to data presented at the American College of Gastroenterology Annual Meeting.
“Immunotherapy is a treatment for a vast number of malignancies with great success in achieving response,” Hamzah Abu-Sbeih, MD, from the University of Texas MD Anderson Cancer Center, said during his presentation. “However, it is common for immunotherapy success to be limited by adverse events with enterocolitis being among the more common

Source link

Related posts

VGLL3 is a prognostic biomarker and correlated with clinical pathologic features and immune infiltrates in stomach adenocarcinoma


Gut pathobionts underlie intestinal barrier dysfunction and liver T helper 17 cell immune response in primary sclerosing cholangitis


Liver Proton Density Fat Fraction Drops After Bariatric Surgery


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy